Crescent Capital BDC Inc (CCAP)
Official siteFINANCIAL SERVICES • ASSET MANAGEMENT • NASDAQ
Market Cap: $373.25M
Last updated: Nov 17, 2026 at 11:04 AM ET
Crescent Capital BDC Inc (CCAP) Stock Forecast
Analysts expect Crescent Capital BDC (CCAP) to earn $1.46 per share in the fiscal year ending Dec 31, 2026, on revenue of $147.29M. Of 7 analysts, 2 rate the stock Buy or Strong Buy, 5 Hold and 0 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 1 estimate for the fiscal year ending Dec 31, 2026 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 2.57, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 29% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 1 | 14.3% |
| Hold | 5 | 71.4% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Hold
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus falls 1.4% and revenue estimates fall 4.0%.
- Fiscal year ending Dec 31, 2026
- $1.46
- EPS consensus, revenue $147.29M
- Fiscal year ending Dec 31, 2027
- $1.44
- EPS consensus, revenue $141.44M
- Next report
- Feb 23, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $1.46 | $1.27 to $1.52 | 5 | $147.29M | $146.11M to $148.90M | 5 |
| Dec 31, 2027 | $1.44 | $1.33 to $1.56 | 6 | $141.44M | $130.41M to $153.21M | 5 |
Quarterly Estimates
The EPS consensus falls from $0.37 for the quarter ending Dec 31, 2026 to $0.35 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $0.37 | $0.33 to $0.41 | 10 | $36.94M | $34.39M to $39.69M | 8 |
| Mar 31, 2027 | $0.35 | $0.33 to $0.38 | 6 | $35.27M | $32.92M to $38.40M | 5 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 3 upward and 5 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 1 | 0 |
| Fiscal year ending Dec 31, 2027 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 1 | 5 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 2.0% from $1.49.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $1.46 | $1.48 | $1.48 | $1.48 | $1.49 | -2.2% |
| Fiscal year ending Dec 31, 2027 | $1.44 | $1.41 | $1.40 | $1.40 | $1.44 | -0.3% |
| Quarter ending Mar 31, 2027 | $0.35 | $0.35 | $0.35 | $0.35 | $0.36 | -1.4% |
Frequently Asked Questions About CCAP
What is the CCAP stock forecast?
Consensus analyst estimates put Crescent Capital BDC's EPS at $1.46 for the fiscal year ending Dec 31, 2026, on revenue of $147.29M. The consensus rating from 7 analysts is Hold.
How do analysts rate CCAP stock?
Of 7 analysts covering Crescent Capital BDC, 1 rates it Strong Buy, 1 Buy, 5 Hold, 0 Sell and 0 Strong Sell, for a consensus of Hold.
What EPS do analysts expect from CCAP next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $1.46, with estimates from $1.27 to $1.52 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $1.44, with estimates from $1.33 to $1.56 from 6 analysts.
What revenue do analysts expect from Crescent Capital BDC next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $147.29M, with estimates from $146.11M to $148.90M. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $141.44M, with estimates from $130.41M to $153.21M.
How many analysts cover CCAP?
7 analysts rate Crescent Capital BDC stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
CCAP pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors